Glaukos Corp., a leader in ophthalmic therapies, upgraded to overweight from neutral by J.P. Morgan. Recent buy ratings and price targets indicate positive sentiment and potential growth for the company. With a market cap of $3.88 billion, Glaukos Corp. is attracting investors with its innovative approach and strong performance.